Abstracts tagged "Biologics and safety"

Abstract Number: 2880 • 2019 ACR/ARP Annual Meeting
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos¹, Laura Coates ², Laure Gossec ³, Slawomir Jeka ⁴, Antonio Mera ⁵, Barbara Schulz ⁶, Michael Rissler ⁶, Ayan Das Gupta ⁷, Chiara Perella ⁶ and Effie Pournara ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²University of Oxford, Oxford, United Kingdom, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁵Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited…